AC Immune (ACIU)
(Delayed Data from NSDQ)
$2.45 USD
+0.26 (11.62%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.49 +0.04 (1.63%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACIU 2.45 +0.26(11.62%)
Will ACIU be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACIU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACIU
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
ACIU: What are Zacks experts saying now?
Zacks Private Portfolio Services
AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
Other News for ACIU
ACIU Reports Strong Cash Position for Future Growth
ACIU Reports Strong Revenue Growth and Progress in Neurodegenerative Therapies
AC Immune GAAP EPS of -CHF0.21, revenue of CHF1.31M
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | ACIU ...
AC Immune reports Q2 EPS (CHF 0.21) vs. (CHF 0.23) last year